Irinotecan as maintenance therapy in high-risk hepatoblastoma

Muna Qayed, Christie Powell, Elaine R. Morgan, Maureen Haugen, Howard M. Katzenstein

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.

Original languageEnglish (US)
Pages (from-to)761-763
Number of pages3
JournalPediatric Blood and Cancer
Issue number5
StatePublished - May 2010


  • Hepatoblastoma
  • Irinotecan
  • Maintenance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Irinotecan as maintenance therapy in high-risk hepatoblastoma'. Together they form a unique fingerprint.

Cite this